EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSG00000116133
Gene: DHCR24
Gene Synonyms: DCE,KIAA0018,SELADIN-1
1 APIs:
6 Enzyme and pathways 9 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSG00000113161
Gene: HMGCR
Gene Synonyms:
10 APIs:
11 Enzyme and pathways 8 Cross references
272 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

3-Phosphoinositide Dependent Protein Kinase 1

Ensembl ID : ENSG00000140992
Gene: PDPK1
Gene Synonyms: PDK1
2 APIs:
72 Enzyme and pathways 7 Cross references
234 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSG00000158104
Gene: HPD
Gene Synonyms: 4-HPPD,4HPPD,GLOD3,PPD
1 APIs:
4 Enzyme and pathways 8 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5'-Nucleotidase Ecto

Ensembl ID : ENSG00000135318
Gene: NT5E
Gene Synonyms: CALJA,CD73,EN,ENT,NT5
1 APIs:
13 Enzyme and pathways 8 Cross references
250 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 1a

Ensembl ID : ENSG00000178394
Gene: HTR1A
Gene Synonyms: 5-HT1A,ADRB2RL1,ADRBRL1
26 APIs:
6 Enzyme and pathways 8 Cross references
150 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSG00000135312
Gene: HTR1B
Gene Synonyms: 5-HT1B,5-HT1DB,HTR1D2,S12
16 APIs:
8 Enzyme and pathways 7 Cross references
244 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 1d

Ensembl ID : ENSG00000179546
Gene: HTR1D
Gene Synonyms: 5-HT1D,HT1DA,HTRL,RDC4
17 APIs:
8 Enzyme and pathways 7 Cross references
67 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSG00000168830
Gene: HTR1E
Gene Synonyms: 5-HT1E
3 APIs:
8 Enzyme and pathways 7 Cross references
157 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSG00000179097
Gene: HTR1F
Gene Synonyms: 5-HT1F,HTR1EL
7 APIs:
8 Enzyme and pathways 7 Cross references
146 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSG00000102468
Gene: HTR2A
Gene Synonyms: 5-HT2A,HTR2
62 APIs:
8 Enzyme and pathways 9 Cross references
217 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSG00000135914
Gene: HTR2B
Gene Synonyms: 5-HT(2B),5-HT2B
10 APIs:
8 Enzyme and pathways 7 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).